| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
INVO Fertility, Inc. Common Stock
$2.36
+1.42 (+146.5%)
Market Cap
1.74 M
EPS
65.77
P/E Ratio
0.01 $
Value Trade
67.88 K
-6.58 %
Week
-6.58 %
1 Month
-35.23 %
3 Month
-80.95 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
71.72 M
52 Week Range
0.90 - 84.40
% held by Insiders
12.11 %
% held by Institutions
9.62 %
Enterprise Value
-357.56 K
Total Shares
1.79 M
Short %
13.54 %
Float Shares
1.78 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
IVF Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IVF
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IVF Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-IVF
Aug 17, 2026▲ +146.5%today
INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability
INVO Fertility reported a 17% increase in revenue for Q2 2026, driven by organic growth and acquisitions. The clinic platform achieved profitability on an Adjusted EBITDA basis, highlighting operational improvements. The company successfully acquired the Birmingham clinic, enhancing its operational control. Despite these positives, it reported a loss from operations and negative Adjusted EBITDA.
Read more →-IVF
Jun 22, 2026▼ -7.3%on this news
INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure
INVO Fertility reported a strong financial performance for Q1 2026, achieving a 23% increase in revenue compared to the previous year. The company eliminated its Series C-2 Preferred Stock and warrant liabilities, significantly improving its balance sheet. Despite a net loss from continuing operations, the overall outlook remains positive due to strategic growth initiatives and acquisitions.
Read more →-IVF
Jun 2, 2026INVO Fertility Announces Fiscal Year 2025 Financial Results
INVO Fertility, Inc. reported a 5% increase in revenue for FY2025, reaching $6.84 million. The company successfully acquired Family Beginnings, expanding its clinic network to four locations. Despite a net loss of $5.3 million, INVO Fertility strengthened its balance sheet through significant financing and continued innovation in reproductive technology. Management expresses optimism for future growth.
Read more →-IVF
Jun 2, 2026INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q
INVO Fertility, Inc. received a notice from Nasdaq regarding its late filing of the 10-K and 10-Q reports. The company is currently working to resolve these issues and has filed the 10-K. Despite the notice, there is no immediate impact on its stock listing, and the company is optimistic about its recent financing and acquisition.
Read more →-IVF
Apr 29, 2026INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
INVO Fertility has received a notification from Nasdaq regarding its late filing of the Annual Report for the fiscal year ended December 31, 2025. The company is currently addressing complex accounting issues and plans to file the report as soon as possible. Despite this notification, INVO's stock remains listed on Nasdaq, and the company has a 60-day window to submit a compliance plan.
Read more →-IVF
Mar 27, 2026▼ -7.1%on this news· ran to -21% by day 1
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on
INVO Fertility, Inc. has announced a 1-for-5 reverse stock split effective March 27, 2026. This move will consolidate the company’s shares, increasing the share price and potentially improving its market presence. Following the split, each holder will exchange five shares for one share, with adjustments made to the authorized shares as well. The company remains focused on offering innovative fertility solutions through its INVOcell medical device and expanding its clinic operations.
Read more →-IVF
Mar 25, 2026▼ -6.2%on this news· ran to -32% by day 3shared move
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
INVO Fertility, Inc. announced a 1-for-5 reverse stock split effective March 27, 2026. This move is aimed at enhancing the company's capital structure and market presence. Post-split, the company's common stock will continue trading under the ticker 'IVF'. The reverse split will reduce the number of outstanding shares while adjusting the authorized shares accordingly.
Read more →-IVF
Mar 5, 2026INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic
INVO Fertility has announced the integration of time-lapse incubation technology at its Wisconsin clinic, enhancing embryo monitoring and assessment. This technology allows for continuous observation of embryo development, supporting informed clinical decisions. Patients will benefit from increased engagement through video records of their embryos, reflecting INVO's commitment to quality and innovative care.
Read more →-IVF
Mar 3, 2026▼ -7%on this newsshared move
INVO Fertility’s Wisconsin Clinic Joins Progyny Network
INVO Fertility's Wisconsin Fertility Institute has joined the Progyny network, enhancing access to fertility services for employer-sponsored patients. This partnership allows WFI to offer a comprehensive suite of reproductive services, increasing its addressable market in Wisconsin. The collaboration aims to improve treatment utilization and outcomes while supporting INVO's growth strategy.
Read more →-IVF
Mar 3, 2026▼ -7%on this newsshared move
INVO Fertility’s Wisconsin Clinic Joins Progyny Network
INVO Fertility's Wisconsin Fertility Institute has joined the Progyny network, enhancing access to employer-sponsored fertility benefits for patients. This partnership allows WFI to provide a comprehensive suite of reproductive services and significantly increases its addressable market. The collaboration aims to improve patient care and support INVO Fertility's growth strategy.
Read more →-IVF
Feb 19, 2026INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility has completed the acquisition of Family Beginnings, a well-regarded fertility clinic in Indiana. This acquisition is part of INVO's strategy to expand its network of fertility care centers. Family Beginnings is known for its personalized approach and comprehensive services, which will now benefit from INVO's resources. The clinic's existing leadership will remain in place to ensure continuity of care.
Read more →-IVF
Feb 19, 2026INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic "Family Beginnings" Strategic Transaction Advances Company's Growth
INVO Fertility, Inc. has successfully completed the acquisition of Family Beginnings, a renowned fertility clinic in Indiana. This strategic move aims to enhance INVO's network of fertility centers, thereby expanding patient access to comprehensive reproductive services. Family Beginnings is recognized for its quality care and has generated significant revenue, contributing positively to INVO's financial performance. The acquisition is expected to further bolster INVO's operations and align with its commitment to patient-centered fertility care.
Read more →-IVF
Feb 11, 2026INVO Fertility Announces Patent Issuance for Modified INVOcell® Device
INVO Fertility has announced the issuance of a U.S. patent for a modified version of its INVOcell device, effective February 10, 2026. This patent extends intellectual property protection until 2040. The INVOcell device, which allows fertilization and early embryo development within the woman's body, represents a significant advancement in assisted reproductive technology. The company aims to enhance fertility care through ongoing innovation.
Read more →-IVF
Feb 11, 2026INVO Fertility Announces Patent Issuance for Modified INVOcell® Device
INVO Fertility has announced the issuance of a U.S. patent for a modified version of its INVOcell device, effective February 10, 2026. This patent secures intellectual property protection until 2040 and reflects the company's commitment to innovation in assisted reproductive technology. The modified INVOcell design simplifies the device for improved patient experience.
Read more →-IVF
Feb 4, 2026▼ -7.8%on this news
INVO Fertility Issues Shareholder Letter Highlighting Strengthened Fundamental Position and Strategic Outlook for Growth
INVO Fertility, Inc. has issued a shareholder letter detailing its strengthened position and growth strategy. The company has achieved profitability at its clinics and is set to acquire a fourth clinic in Indianapolis. With a focus on organic growth and acquisitions, INVO aims to expand its operational footprint and enhance its revenue base. The CEO expresses optimism about the company's future, supported by a strong balance sheet and favorable policy changes in fertility care.
Read more →-IVF
Jan 29, 2026▼ -13%on this news· ran to -28% by day 3
INVO Fertility Enters into $7.5 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
INVO Fertility Inc. has entered a warrant inducement agreement to exercise outstanding warrants, generating approximately $7.5 million. The investor will acquire shares at a reduced price of $1.59 each. Additionally, new warrants will be issued, pending shareholder approval. The transaction is expected to close around January 30, 2026.
Read more →-IVF
Jan 13, 2026INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
INVO Fertility, Inc. will participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026. The company focuses on establishing and operating fertility clinics, particularly offering the innovative intravaginal culture procedure through its INVOcell device. The webcast is scheduled for 3:00 p.m. ET and will be accessible online.
Read more →-IVF
Dec 30, 2025▼ -7.7%on this news
INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy
INVO Fertility has announced a restructuring of its executive leadership to support its growth strategy in the fertility sector. Terah Krigsvold has been appointed as the new CFO, while Andrea Goren transitions to chief business officer. This realignment is aimed at enhancing the company's ability to execute its plans for acquisitions and new clinic launches.
Read more →-IVF
Dec 30, 2025▲ +10%on this news· ran to +36% by day 3shared move
INVO Fertility Aligns Executive Leadership Structure to Support Growth Strategy Terah Krigsvold to replace Andrea Goren as CFO, who is named chief business officer and CEO of INVO Centers LLC to focus on growth efforts
INVO Fertility, Inc. has announced a restructuring of its executive leadership to support its growth strategy in the fertility sector. Terah Krigsvold replaces Andrea Goren as CFO, while Goren takes on the role of chief business officer and CEO of INVO Centers LLC. The changes aim to enhance the company's ability to acquire and establish fertility clinics, with Goren focusing on new clinic launches and strategic partnerships. This realignment is part of INVO's overall strategy to expand its presence and profitability in the fertility market.
Read more →-IVF
Dec 17, 2025▼ -9.7%on this news· ran to -25% by day 3
INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility has signed a definitive purchase agreement to acquire Family Beginnings, a respected fertility clinic in Indiana. This acquisition aims to enhance INVO's presence in the fertility care sector and is expected to close by February 27, 2026. Family Beginnings generated approximately $1.2 million in revenue and is known for its personalized care model.
Read more →-IVF
Dec 17, 2025▼ -9.7%on this news· ran to -25% by day 3shared move
INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic "Family Beginnings" Signing of definitive purchase agreement represents critical next step in completing previously announced a
INVO Fertility, Inc. has announced the definitive purchase agreement to acquire Family Beginnings, a well-respected fertility clinic in Indiana. This acquisition is a strategic move to expand INVO's footprint of fertility care centers across the United States. Family Beginnings reported revenues of approximately $1.2 million in the last year, with plans for integration into INVO's operations expected by February 27, 2026. The acquisition is partially financed through the issuance of preferred stock and cash payments, and will enhance INVO's mission of providing advanced fertility care solutions.
Read more →-IVF
Dec 2, 2025▼ -11.8%on this news
INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
INVO Fertility, Inc. has announced the successful pricing of a $4.0 million private placement, involving the sale of 2,366,864 shares of common stock and accompanying warrants for additional shares. The offering price is set at $1.69 per share, with the company expecting to close the transaction on December 3, 2025, pending customary conditions. The funds raised will support the company's initiatives in expanding assisted reproductive technology services and operations related to their proprietary medical device, INVOcell.
Read more →-IVF
Nov 28, 2025INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility has announced its intent to acquire Family Beginnings, a respected fertility clinic in Indiana. This marks INVO's second acquisition as part of its strategy to expand its nationwide network of fertility centers. The partnership aims to enhance treatment options and improve patient care through innovative technologies. The acquisition is pending due diligence and regulatory approvals.
Read more →-IVF
Nov 28, 2025INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility has announced its intent to acquire Family Beginnings, a fertility clinic based in Indiana. This acquisition aligns with INVO's strategy to build a nationwide network of fertility centers and enhance patient access to reproductive services. Family Beginnings is known for its high standards of care and successful treatment options. The deal is expected to close soon, pending due diligence and regulatory approvals.
Read more →-IVF
Nov 28, 2025▲ +11%on this newsshared move
INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on
INVO Fertility, Inc. announced a 1-for-8 reverse stock split effective November 28, 2025, aiming to stabilize its share price. Following this action, the company will have approximately 1.89 million shares outstanding. INVO continues to focus on expanding its fertility clinic operations and the distribution of its INVOcell medical device. Despite optimistic growth strategies, uncertainties regarding future financial performance and market conditions persist.
Read more →-IVF
Nov 25, 2025▼ -20.2%on this news· ran to -34% by day 3shared move
INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025
INVO Fertility, Inc. announced a 1-for-8 reverse stock split effective November 28, 2025. This move will adjust the number of shares outstanding and authorized, aiming to improve the company's stock performance. The common stock will continue to trade under the symbol 'IVF' post-split. INVO Fertility focuses on expanding assisted reproductive technology through its innovative INVOcell device.
Read more →-IVF
Nov 17, 2025▼ -5.1%on this news· ran to -36% by day 3
INVO Fertility Announces Third Quarter 2025 Financial Results
INVO Fertility, Inc. reported its third quarter 2025 financial results, revealing a 23% increase in revenue compared to the previous year, reaching $1,757,094. The company experienced strong growth from its fertility clinics in Georgia and Wisconsin, contributing to an 18% increase in total revenue across all clinics. Despite these positive results, the company posted a net loss of $2.6 million, up from $1.6 million last year. INVO Fertility noted substantial growth in its INVOcell device revenue, alongside promising policy changes that may enhance access to IVF treatments nationwide.
Read more →-IVF
Oct 27, 2025▼ -7.4%on this news· ran to -20% by day 3
INVO Fertility Partners with Heidi Health to Bring AI-Powered Tools to INVO’s Wisconsin Fertility Institute
INVO Fertility has partnered with Heidi Health to implement AI-powered tools at its Wisconsin Fertility Institute. This integration aims to automate clinical documentation, allowing clinicians to focus more on patient care. The technology is expected to significantly reduce the administrative workload, enhancing the overall patient experience in fertility treatments.
Read more →-IVF
Sep 29, 2025▼ -7.2%on this news
INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
INVO Fertility, Inc. will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025. The company will host a webcast presentation and offer one-on-one meetings with investors. INVO Fertility aims to expand access to assisted reproductive technology through its clinics and innovative medical devices.
Read more →-IVF
Aug 14, 2025INVO Fertility Announces Second Quarter 2025 Financial Results
INVO Fertility, Inc. reported its financial results for Q2 2025, highlighting a 1% increase in revenue to $1,863,654, marking a new quarterly record. However, the company also experienced a greater net loss of $(3.2) million compared to the same period in the prior year. Efforts to innovate include launching telehealth capabilities and adding PRP therapy services, enhancing patient access and treatment options. Additionally, a new patent for an improved INVOcell device has been granted, while the company divested its majority stake in NAYA Therapeutics to focus more on fertility-related operations.
Read more →-IVF
Jul 21, 2025INVO Fertility Announces a 1:3 Reverse Stock Split Effective Pre-Market Opening on
INVO Fertility, Inc. announced a 1-for-3 reverse stock split effective July 21, 2025, as a strategy to comply with Nasdaq's minimum bid price requirement. This action will reset the company's stock price while retaining its trading symbol 'IVF'. Post-split, the company will have around 928,272 shares of common stock outstanding. INVO Fertility specializes in assisted reproductive technology, highlighting its proprietary INVOcell medical device that aims to improve patient experiences and outcomes.
Read more →-IVF
Jul 17, 2025INVO Fertility Announces a 1:3 Reverse Stock Split Effective Pre-Market Opening on July 21, 2025
INVO Fertility, Inc. announced a 1-for-3 reverse stock split effective July 21, 2025, to meet Nasdaq's minimum bid price requirement. Post-split, the company will have approximately 928,272 shares outstanding. The split is part of a strategy to maintain its listing, although compliance is not assured. INVO Fertility focuses on expanding assisted reproductive technology through its INVOcell device.
Read more →-IVF
Jul 9, 2025INVO Fertility Enhances INVOcell Technology with Expanded Awareness, Training, and Improved Pricing
INVO Fertility has announced enhancements to its INVOcell technology, focusing on expanded training and improved pricing to make the service more accessible. The INVOcell system, which allows fertilization within the woman's body, offers comparable pregnancy rates to traditional IVF. The company aims to increase market awareness through targeted educational campaigns and is dedicated to democratizing fertility care.
Read more →-IVF
Jun 30, 2025INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute
INVO Fertility has introduced Platelet-Rich Plasma (PRP) therapy at its Wisconsin Fertility Institute. This innovative treatment aims to enhance fertility outcomes for individuals facing challenges such as a thin uterine lining or diminished ovarian reserve. The therapy is designed to be a minimally invasive alternative before considering more invasive options like egg donation. Experts express optimism about its potential benefits in reproductive medicine.
Read more →-IVF
Jun 25, 2025▼ -16.4%on this news· ran to -28% by day 3shared move
INVO Fertility Receives Notice of Allowance for Modified INVOcell Device Patent
INVO Fertility has announced the receipt of a Notice of Allowance for a new patent on a modified INVOcell device, which extends its intellectual property protection until 2040. The redesigned device incorporates feedback from embryologists to enhance usability. The INVOcell system, which allows fertilization and embryo development within the body, continues to show promising success rates comparable to traditional IVF methods.
Read more →-IVF
Jun 20, 2025INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time
INVO Fertility is urging shareholders to vote for proposals at the upcoming Annual Meeting on June 25, 2025. The Board of Directors recommends voting 'FOR' all proposals to support growth strategies, including acquisitions and technology expansion. Shareholders can vote online, by mail, or by phone, and the meeting will be conducted virtually.
Read more →-IVF
Jun 18, 2025INVO Fertility Expands Telehealth Capabilities at Its Wisconsin Fertility Institute
INVO Fertility has expanded its telehealth services at the Wisconsin Fertility Institute, allowing prospective parents to access expert fertility care from home. This initiative enhances accessibility, particularly for those in underserved regions. Patients can receive personalized assessments and treatment planning through secure virtual consultations, while in-clinic procedures remain at the facility. The expansion aims to support more families on their journey to parenthood.
Read more →-IVF
Jun 16, 2025INVO Fertility’s Wisconsin Clinic Recognized on Newsweek’s List of America’s Best Fertility Clinics for 2025
INVO Fertility's Wisconsin Fertility Institute has been recognized by Newsweek as one of America's Best Fertility Clinics for 2025. This accolade is based on quality metrics, a nationwide survey of medical professionals, accreditation data, and patient satisfaction. CEO Steve Shum expressed pride in the team's commitment to high-quality fertility care.
Read more →-IVF
May 27, 2025INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
INVO Fertility, Inc. will participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The company will host a webcast presentation and one-on-one meetings with investors. INVO Fertility focuses on expanding access to assisted reproductive technology through its INVO Centers and proprietary INVOcell device, which enhances the IVF process.
Read more →-IVF
May 20, 2025▼ -10.3%on this news· ran to -24% by day 3shared move
INVO Fertility Announces First Quarter 2025 Financial Results
INVO Fertility, Inc. reported its Q1 2025 financial results, showing a 4% increase in revenue year-over-year. However, the company faced a significant net loss of $(17.4) million, largely due to an impairment charge related to NAYA Therapeutics. INVO Fertility is divesting a majority stake in NAYA TX to refocus on its core fertility services and expand clinic operations.
Read more →-IVF
May 20, 2025INVO Fertility Announces First Quarter 2025 Financial Results Company now exclusively focused on the growing fertility market following the April 2025 announcement to divest a majority stake in Naya Therapeutics
INVO Fertility has reported its first quarter 2025 financial results, which revealed a 4% revenue increase compared to the previous year, reaching $1,637,185. Despite some growth in consolidated clinic revenue, the company experienced a significant net loss of $17.4 million, primarily due to a large impairment charge associated with its NAYA Therapeutics asset. The company has announced a strategic refocus on the fertility market following the decision to divest a majority stake in NAYA Therapeutics, with plans to accelerate clinic growth and explore further acquisitions in the fertility sector.
Read more →-IVF
Apr 30, 2025▼ -5.2%on this news· ran to -25% by day 1
INVO Fertility Confirms New Nasdaq Trading Symbol of “IVF”
INVO Fertility, Inc. will start trading under the new Nasdaq symbol 'IVF' on April 28, 2025. This change aligns with the company's strategic decision to focus on the fertility market, separating its fertility and oncology businesses. CEO Steve Shum emphasized the commitment to expanding access to fertility services and innovative reproductive technologies.
Read more →-IVF
Apr 30, 2025▲ +48.4%on this newsshared move
INVO Fertility Announces 2024 Financial Results with 116% Annual Revenue Growth and Further Improvements in Adjusted
INVO Fertility, Inc. reported significant financial results for 2024, marking a 116% annual revenue growth compared to the previous year, with consolidated clinic revenue also seeing a notable increase. Despite this growth, the company experienced a greater net loss of $(9.1) million, attributed mainly to the merger with NAYA Therapeutics. Adjusted EBITDA showed improvement, and the company plans to focus on expanding its fertility operations amidst a favorable market landscape. INVO Fertility aims to enhance access to fertility care through its operational clinics across the U.S.
Read more →-IVF
Apr 14, 2025NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”
INVO Fertility, Inc., formerly NAYA Biosciences, has announced a strategic separation of its fertility and oncology operations. The company will focus on building and operating fertility clinics and distributing its FDA-cleared INVOcell device. NAYA Therapeutics will operate independently, concentrating on the clinical development of bifunctional antibodies. This separation aims to enhance shareholder value and operational focus for both entities.
Read more →-IVF
Mar 18, 2025NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on
NAYA Biosciences, Inc. announced a 1-for-12 reverse stock split effective March 18, 2025, to comply with Nasdaq's minimum bid price requirement. Following the split, the stock will continue trading under the symbol "NAYA". The company aims to stabilize its stock value to maintain its listing, although there are no guarantees of achieving compliance post-split. NAYA is involved in several clinical-stage therapeutics, with ongoing trials for various cancer treatments.
Read more →-IVF
Mar 13, 2025NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
NAYA Biosciences, Inc. announced a 1-for-12 reverse stock split effective March 18, 2025, to comply with Nasdaq's minimum bid price requirement. Following the split, the company's common stock will continue trading under the symbol 'NAYA'. The adjustment will result in approximately 666,057 shares outstanding, with authorized shares set at 4,166,666. However, the company cautions that compliance is not assured.
Read more →-IVF
Feb 25, 2025NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment
NAYA Biosciences supports a recent executive order by the U.S. President aimed at reducing the costs of in vitro fertilization (IVF) and expanding access to fertility services. The order mandates the Domestic Policy Council to create recommendations to lower out-of-pocket expenses for families dealing with infertility. NAYA emphasizes the importance of affordable fertility treatments and its commitment to patient-centered care.
Read more →-IVF
Feb 19, 2025NAYA Biosciences Announces Nomination of New Board Members
NAYA Biosciences has nominated five new board members with significant experience in biotechnology to be approved at the upcoming shareholder meeting. This move reflects the company's strategic focus on oncology and autoimmune diseases. The new members include leaders from various successful biotech firms, enhancing NAYA's leadership capabilities as it seeks to develop innovative treatments.
Read more →-IVF
Jan 13, 2025NAYA Biosciences Announces Pricing of $9.5 Million Public Offering
NAYA Biosciences has announced the pricing of a public offering of 13,615,171 units at $0.70 each, aiming to raise approximately $9.5 million. The funds will be allocated towards the purchase of the Wisconsin Fertility Institute, debt obligations, and various corporate purposes. The offering is expected to close on January 14, 2025, subject to customary conditions.
Read more →-IVF
Jan 13, 2025NAYA Biosciences Announces Pricing of $9.5 Million Public Offering SARASOTA, Fla. and MIAMI
NAYA Biosciences announced the pricing of a public offering totaling $9.5 million, offering 13,615,171 units at $0.70 per unit. The company intends to utilize the proceeds for a variety of purposes including acquisitions, clinical trials, and debt obligations. The offering is expected to close around January 14, 2025, pending customary closing conditions. This move reflects NAYA's plans to expand its portfolio and operational capabilities in the life sciences sector.
Read more →-IVF
Jan 6, 2025NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody
NAYA Biosciences announced the development of NY-500, a novel PD-1 x VEGF bifunctional antibody aimed at treating hepatocellular carcinoma and other solid tumors. The company plans to initiate clinical trials in early 2026, leveraging AI technology to enhance its drug design. Recent data indicates that PD-1 x VEGF antibodies may outperform existing therapies like Keytruda in certain cancer types.
Read more →-IVF
Dec 12, 2024NAYA THERAPEUTICS, INC. (FORMER NAME NAYA BIOSCIENCES, INC.) FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 TABLE OF CONTENTS Contents REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. 2 BALANCE SHEETS 4 STATEMENT
Naya Therapeutics, Inc. has reported its financial results for the years ended December 31, 2023 and 2022, reflecting continued operational losses. The audit opinion indicates that the financial statements fairly present the company's position, though substantial doubts about the company's viability persist due to significant net losses and negative working capital. The company is operating under a going concern assumption, highlighting ongoing financial challenges.
Read more →-IVF
Oct 31, 2024NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
NAYA Biosciences announced its presentation of insights on its GPC3-targeting NK engager bispecific antibody, NY-303, at the upcoming SITC 2024 meeting. The data suggests NY-303 can reverse PD-1 checkpoint blockade resistance in hepatocellular carcinoma (HCC) and improve patient outcomes. The company aims to support Phase I/IIa trials starting in early 2025.
Read more →-IVF
Oct 24, 2024NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma
NAYA Biosciences has announced the initiation of a Phase 1/2a clinical trial for its GPC3-targeted NK Engager bispecific antibody, NY-303, aimed at treating hepatocellular carcinoma (HCC) patients who do not respond to first-line immunotherapy. The trial will begin patient enrollment in early 2025 across several academic centers in Israel. This innovative therapy seeks to improve treatment outcomes for HCC, which has a high mortality rate and limited effective options.
Read more →-IVF
Oct 21, 2024INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
INVO Biosciences has officially changed its corporate name to NAYA Biosciences Inc. following its merger with NAYA Biosciences. The company will begin trading under the new symbol 'NAYA' on October 22, 2024. This change aligns with its strategy to enhance its portfolio in fertility, oncology, and autoimmune diseases, while continuing to operate its revenue-generating fertility business.
Read more →-IVF
Oct 14, 2024INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
INVO Bioscience has successfully merged with NAYA Biosciences, forming a new entity that will operate under the name NAYA Biosciences. The merger aims to enhance patient access to innovative treatments in oncology and autoimmune diseases while maintaining a revenue-generating fertility business. The combined company will be led by a team of experienced executives from both organizations.
Read more →-IVF
Oct 14, 2024INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA) Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and aut
INVO Bioscience has successfully completed its merger with NAYA Biosciences, which will operate under the name NAYA Biosciences on NASDAQ. The merger aims to enhance the combined company's offerings in fertility, oncology, and autoimmune disease treatments. Leadership will be shared among INVO executives and former leaders from NAYA, promising a collaborative approach. The new entity is poised to benefit from combined assets and revenue streams while advancing its clinical-stage therapeutic pipelines.
Read more →-IVF
Aug 14, 2024INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted
INVO Bioscience, Inc. reported exceptional financial results for Q2 2024, achieving a record revenue growth of 481% compared to the same quarter in 2023. The increase in revenue was primarily driven by substantial gains from their fertility clinics, which have also become profitable. Despite a net loss remaining unchanged at $(2.2) million, the company reported a $1.1 million improvement in adjusted EBITDA, reflecting improved operational efficiency. Future plans include further acquisitions and expanding clinic services to enhance patient access to advanced fertility treatments.
Read more →-IVF
May 15, 2024INVO Reports Record First Quarter 2024 Financial Results
INVO Bioscience reported a record revenue of $1.58 million for Q1 2024, marking a 353% increase from the previous year. The company also noted a significant improvement in adjusted EBITDA, indicating effective management of operating expenses. INVO is optimistic about achieving profitability in 2024, despite a net loss of $1.6 million. The planned merger with NAYA Biosciences remains contingent on certain conditions.
Read more →-IVF
May 15, 2024INVO Reports Record First Quarter 2024 Financial Results 353% Revenue Growth with improvement in Adjusted
INVO Bioscience, Inc. reported impressive financial results for Q1 2024, with a notable revenue increase of 353% from the previous year, totaling $1.57 million. The company also reported an improved adjusted EBITDA loss of $0.5 million, reflecting better cost management. INVO aims to expand its footprint in the fertility market through strategic initiatives and a proposed merger with NAYA Biosciences, which will enhance access to advanced treatment options. The company remains optimistic about reaching profitability in 2024.
Read more →-IVF
Apr 16, 2024INVO Reports Fourth Quarter and Full Year 2023 Financial Results
INVO Bioscience, Inc. reported substantial financial growth for Q4 and the full year of 2023, highlighting a revenue increase of 397% in the fourth quarter compared to the previous year. The company decreased its total operating expenses and improved its adjusted EBITDA, reflecting progress towards profitability. However, INVO continues to face net losses and is contingent on the successful merger with NAYA Biosciences, which introduces uncertainties regarding future operations.
Read more →-IVF
Dec 11, 2023NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology’s Blood Journal
NAYA Biosciences has announced the publication of new data for its CD38-targeted Flex-NK™ Bispecific Antibody, NY-338, which demonstrates a differentiated profile from daratumumab, indicating best-in-class potential for treating Multiple Myeloma. The data supports the initiation of clinical trials in 2024. Additionally, NAYA is set to merge with INVO Bioscience, enhancing its capabilities in life sciences.
Read more →-IVF
Dec 6, 2023NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
NAYA Biosciences and ONK Therapeutics have formed a research partnership to explore the combination of NAYA's FLEX-NK™ bispecific antibodies and ONK's engineered NK cell therapies for cancer treatment. The collaboration aims to assess the feasibility and activity of this combination, with potential for further clinical development. This approach targets significant unmet needs in hepatocellular carcinoma.
Read more →-IVF
Nov 28, 2023INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
INVO Bioscience has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, as confirmed by a notice from Nasdaq. This follows a share exchange agreement with Cytovia Therapeutics, which bolstered INVO's financial standing. Despite previous non-compliance, the company has shown a significant reduction in net loss and is continuing efforts towards a merger with NAYA Biosciences.
Read more →-IVF
Nov 28, 2023INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
INVO Bioscience, Inc. has announced that it has regained compliance with the Nasdaq minimum stockholders' equity requirement, following a successful share exchange with Cytovia Therapeutics. The exchange and a notable decrease in net loss have enabled the company to meet the necessary equity threshold required for continued Nasdaq listing. INVO is also proceeding with a merger agreement with NAYA Biosciences, focusing on enhancing oncology and regenerative medicine treatments. Following this compliance notification, the company will be monitored for one year to ensure ongoing adherence to Nasdaq regulations.
Read more →-IVF
Nov 13, 2023INVO Reports Record Third Quarter 2023 Financial Results
INVO Bioscience reported a record revenue of $974,894 for Q3 2023, marking a 314% increase year-over-year. The company also announced a merger agreement with NAYA Biosciences, which is expected to enhance its growth in fertility and oncology sectors. Despite a net loss of $(1.2) million, the clinics generated positive net income when excluding corporate costs, indicating a path towards profitability.
Read more →-IVF
Nov 13, 2023INVO Reports Record Third Quarter 2023 Financial Results Company Expects to Host Conference Call Shortly After
INVO Bioscience reported a record revenue of $974,894 for Q3 2023, marking a significant increase of 314% compared to the prior year. The company has made strategic moves, including the acquisition of the Wisconsin Fertility Institute and a merger agreement with NAYA Biosciences aimed at enhancing its healthcare services. Despite a net loss of $(1.2) million, there are signs of progress towards profitability, with an expected conference call set to discuss further details post-November 20, 2023.
Read more →-IVF
Nov 10, 2023NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
NAYA Biosciences and INVO Bioscience have announced the appointment of Dr. Peter Kash as Vice Chairman following their pending merger. Dr. Kash brings over 36 years of experience in the biotech industry and is expected to contribute significantly to the combined company's growth strategy. The merger aims to enhance patient access to advanced fertility treatments and innovative therapies in oncology and regenerative medicine.
Read more →-IVF
Nov 9, 2023INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company’s Common Stock Purchase Warrants
INVO Bioscience has initiated a waiver solicitation from holders of its common stock purchase warrants as a condition for completing its merger with NAYA Biosciences. The solicitation will expire on November 15, 2023, and is part of the necessary steps to finalize the proposed transaction. Further details will be provided in a Form 8-K filing with the SEC.
Read more →-IVF
Nov 9, 2023INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants
INVO Bioscience, Inc. has announced the commencement of a waiver solicitation from holders of its common stock purchase warrants in connection with the proposed merger with NAYA Biosciences, Inc. This solicitation is necessary to meet conditions for merging with NAYA. The waiver solicitation will expire on November 15, 2023, and holders will receive detailed terms through a formal notice. The transaction remains contingent upon various approvals and may encounter risks such as potential litigation or regulatory hurdles.
Read more →-IVF
Oct 27, 2023Free Registration Is Now Open For Tribe Public’s CEO and Q&A Presentation Webinar Event “Accelerating Biotech Value Creation” Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023
NAYA Biosciences CEO Dr. Daniel Teper will present at Tribe Public's webinar titled 'Accelerating Biotech Value Creation' on October 31, 2023. The event aims to discuss increasing patient access to innovative treatments in oncology, regenerative medicine, and fertility. Participants can register for free and submit questions during the event.
Read more →-IVF
Oct 23, 2023INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
INVO Bioscience and NAYA Biosciences have announced a definitive merger agreement to create a new entity named NAYA Biosciences. This merger aims to enhance patient access to treatments in oncology, fertility, and regenerative medicine. The combined company will leverage NAYA's innovative technologies and INVO's established network of fertility clinics. The merger is expected to close in Q4 2023, pending shareholder approvals.
Read more →-IVF
Oct 23, 2023INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company Post-merger, the combined company, operating under the name "NAYA Biosciences", will be
INVO Bioscience has announced a definitive merger agreement with NAYA Biosciences, aiming to create a larger publicly traded entity named NAYA Biosciences. This merger focuses on expanding patient access to innovative treatments in oncology, fertility, and regenerative medicine. The transaction involves an all-stock agreement whereby NAYA shareholders will receive INVO shares. Post-merger, the combined company will leverage NAYA's technological strengths and INVO's existing operations to enhance growth and patient care. The merger is expected to close in Q4 of 2023, pending necessary approvals.
Read more →-IVF
Oct 11, 2023INVO to Participate in the Lytham Partners Fall 2023 Investor Conference
INVO Bioscience, Inc. will participate in the Lytham Partners Fall 2023 Investor Conference, with CEO Steve Shum presenting on a panel about advanced fertility technologies. The event will take place on October 17, 2023, and includes opportunities for virtual one-on-one meetings with management. INVO aims to expand access to its INVOcell® device and IVC procedure.
Read more →-IVF
Sep 29, 2023INVO BIOSCIENCE ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF SHAREHOLDERS
INVO Bioscience announced the adjournment of its special meeting of shareholders, originally scheduled for September 29, 2023, to allow more time for voting on key proposals. The meeting will reconvene on October 13, 2023. Shareholders are encouraged to vote on proposals to increase authorized shares and reduce warrant exercise prices. Current voting indicates strong support for one proposal but challenges for another.
Read more →-IVF
Sep 28, 2023INVO Reminds Shareholders to Cast Their Vote for Upcoming Special Meeting of Shareholders to be held on Friday, September 29, 2023 at 12:00 p.m. ET
INVO Bioscience, Inc. is urging shareholders to vote in the upcoming special meeting scheduled for September 29, 2023. The Board recommends voting 'FOR' all proposals, which include increasing authorized shares and reducing warrant exercise prices. Shareholders can vote online, by mail, or during the virtual meeting. The company emphasizes the importance of participation in shaping its future.
Read more →-IVF
Aug 14, 2023INVO Reports Second Quarter 2023 Financial Results
INVO Bioscience, Inc. reported a strong financial performance for Q2 2023, with a 116% revenue increase compared to the same period last year. The company successfully acquired the Wisconsin Fertility Institute, enhancing its operational scale. Despite these positive developments, INVO reported a net loss of $2.24 million and continues to focus on achieving profitability through strategic expense reductions and operational improvements.
Read more →-IVF
Aug 14, 2023INVO Reports Second Quarter 2023 Financial Results Company to Host Conference Call Today at 4:30pm
INVO Bioscience, Inc. reported a significant revenue boost of 116% in Q2 2023 compared to the same quarter last year, totaling $315,902. The company also announced the successful acquisition of the Wisconsin Fertility Institute, which will enhance its operational capabilities. Furthermore, INVO indicated that cost-cutting measures are in place to steer the company towards profitability by 2024, along with recent FDA clearance for the INVOcell device. These developments posit the firm for potentially sustainable growth in the fertility services market.
Read more →-IVF
Aug 11, 2023INVO Closes Acquisition of Wisconsin Fertility Institute
INVO Bioscience has successfully completed the acquisition of Wisconsin Fertility Institute, enhancing its operational scale and revenue potential. This strategic move is part of INVO's plan to integrate its innovative INVOcell technology into existing fertility services. The acquisition is expected to generate over $5 million in annual revenue and strengthen INVO's position in the fertility market.
Read more →-IVF
Aug 11, 2023INVO Closes Acquisition of Wisconsin Fertility Institute Transformational and accretive acquisition adds significant scale to INVO's current operations Contributes over $5 million in incremental annual revenue as well as
INVO Bioscience, Inc. has successfully closed its acquisition of the Wisconsin Fertility Institute, significantly enhancing its operational capabilities and revenue potential. The acquisition is projected to contribute over $5 million in annual revenue and is part of INVO's strategy to establish itself as a leader in healthcare services focused on fertility. The Madison-based center will help INVO further its innovative intravaginal culture (IVC) procedures while integrating the Wisconsin Fertility Institute’s established practices. This acquisition marks a key step in INVO's growth and commercialization plans within the assisted reproductive technology sector.
Read more →-IVF
Aug 9, 2023INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
INVO Bioscience, Inc. will report its second quarter 2023 financial results on August 14, 2023, after market close. A conference call is scheduled for the same day at 4:30 pm ET to discuss the results. The company focuses on making fertility care more accessible through its innovative INVOcell medical device and IVC procedure.
Read more →-IVF
Aug 8, 2023INVO Bioscience Announces Closing of $4.5 Million Public Offering
INVO Bioscience has announced the successful closing of a public offering, raising approximately $4.5 million. The offering consisted of 1,580,000 units, each comprising one share of common stock and two warrants. This funding will support the company's mission to expand access to its innovative INVOcell® medical device and related fertility services.
Read more →-IVF
Aug 4, 2023INVO Bioscience Announces Pricing of $4.5 Million Public Offering
INVO Bioscience has announced a public offering priced at $4.5 million, involving 1,580,000 units, each comprising one share of common stock and two warrants. This move is part of their strategy to expand access to their INVOcell medical device and IVC procedure. The offering is scheduled to close on August 8, 2023, subject to customary closing conditions, and is facilitated by Maxim Group LLC as the sole placement agent. INVO aims to enhance fertility treatment accessibility through its innovative technology and clinic expansion plans.
Read more →-IVF
Aug 3, 2023INVO Sets Revised Closing Date of Wisconsin Fertility Institute Acquisition and Announces Key Operational Trends to Drive Shareholder Value
INVO Bioscience has extended the closing date for its acquisition of Wisconsin Fertility Institute to August 10, 2023. This acquisition is anticipated to enhance revenue and net income significantly, transitioning INVO from a medical device company to a healthcare services provider. The company aims for cash flow breakeven by 2024, supported by recent FDA clearance and operational cost reductions.
Read more →-IVF
Jul 28, 2023INVO Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on
INVO Bioscience, Inc. announced a 1-for-20 reverse stock split set to take effect on July 28, 2023. This action aims to bring the company's stock into compliance with Nasdaq's minimum bid price requirement. Alongside this split, adjustments will be made to both issued and authorized shares. The company continues to pursue its mission of expanding access to advanced fertility treatments, although it acknowledges the risks associated with meeting compliance standards in the future.
Read more →-IVF
Jul 27, 2023INVO Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on July 28, 2023
INVO Bioscience, Inc. announced a 1-for-20 reverse stock split effective July 28, 2023, to comply with Nasdaq's minimum bid price requirement. Following the split, the company will have approximately 842,017 shares outstanding and 6,250,000 authorized shares. While this move aims to improve market standing, there are no guarantees it will achieve compliance.
Read more →-IVF
Jun 30, 2023INVO BIOSCIENCE, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On
INVO Bioscience Inc. has entered into agreements to acquire the Wisconsin Fertility Institute for a total purchase price of $10 million. The payment will be made in four installments, with options for sellers to receive shares of INVO common stock. The deal includes the acquisition of a medical practice and related laboratory services, but excludes certain non-clinical assets. The financial statements provided are unaudited and meant for informational purposes, outlining expected operational impacts post-acquisition.
Read more →-IVF
Jun 21, 2023WISCONSIN FERTILITY AND REPRODUCTIVE SURGERY ASSOCIATES, S.C. AND FERTILITY LABS OF WISCONSIN, LLC AUDITED COMBINED FINANCIAL STATEMENTS As of and for the years ended
The article provides the audited combined financial statements for Wisconsin Fertility and Reproductive Surgery Associates, S.C. and Fertility Labs of Wisconsin, LLC for the years ending December 31, 2022 and 2021. The financial statements have been audited by an independent public accounting firm and present a fair view of the companies' financial position. While net income remains strong, there has been a decrease in overall revenue, and the members' deficit has increased significantly, suggesting challenges ahead.
Read more →-IVF
May 15, 2023INVO Reports First Quarter 2023 Financial Results Company to Host Conference Call Today at 4:30pm
INVO Bioscience, Inc. reported substantial financial results for the first quarter of 2023, showing a revenue increase of 114% compared to the same period in 2022. The company announced the acquisition of Wisconsin Fertility Institute to bolster its service offerings and enhance profitability. Additionally, INVO successfully expanded its gross margin to 79% through improved efficiencies. Furthermore, construction for the new Tampa Fertility Institute is on track for a mid-summer opening, supporting the company's goal of increasing accessibility to affordable fertility care.
Read more →-IVF
Apr 17, 2023INVO Reports Fourth Quarter and Full Year 2022 Financial Results Company to Host Conference Call Today at 4:30pm
INVO Bioscience, Inc. reported its financial results for the fourth quarter and fiscal year 2022, with total revenue significantly down by approximately 80% year-over-year. Despite a 726% increase in revenue from clinics, the overall financial performance was impacted by the termination of a previous agreement with Ferring, leading to substantial losses. The company is targeting the opening of a new INVO Center in Tampa, Florida, and is pursuing an acquisition strategy aimed at integrating its technology into existing IVF clinics. INVO's operational costs have also risen, particularly in general and administrative expenses.
Read more →-IVF
Mar 31, 2023RESIGNATION
Jeffrey Segal, MD has submitted his resignation as a director of INVO Bioscience, effective immediately. He has clarified that his resignation is not due to any disagreements regarding the company's operations, policies, or practices. The abrupt nature of the resignation could raise questions among company stakeholders about its implications.
Read more →-IVF
Mar 30, 2023INVO Provides Preliminary Update on FY2022 Financial Results
INVO Bioscience, Inc. has announced preliminary financial results for FY2022, indicating an expected revenue growth of 38% to 40% compared to the previous year, despite a significant decline in revenue caused by the end of its agreement with Ferring. The company is optimistic about its future financial performance following the recent signing of purchase agreements for its initial IVF clinic. Additionally, INVO's ongoing growth in revenue from its INVO Center clinics is expected to support its strategic expansion. However, the company's revenue for 2022 is anticipated to be approximately 80% lower than in 2021, necessitating an extension for filing its Annual Report with the SEC.
Read more →-IVF
Mar 24, 2023INVO Bioscience Announces Pricing of $3.0 Million Registered Direct Offering Priced At-The-Market SARASOTA, FL - (
INVO Bioscience, Inc. has announced a registered direct offering priced at-the-market, aimed at raising approximately $3.0 million. The company will sell 3,680,000 shares and has included warrants for additional shares. This fundraising initiative is part of its strategy to expand access to its INVOcell fertility treatment. The closing of the offering is anticipated on or about March 27, 2023, pending regulatory conditions.
Read more →-IVF
Mar 20, 2023INVO Signs Binding Agreements to Acquire Wisconsin Fertility Institute Accretive acquisition expected to add significant scale to INVO's operations Contributes over $5 million in incremental a nnual revenue as well as po
INVO Bioscience, Inc. has signed agreements to acquire the Wisconsin Fertility Institute, aiming to enhance its commercial operations significantly. This acquisition is projected to generate over $5 million in incremental annual revenue and positive net income. As a result, the Wisconsin Fertility Institute will become a wholly owned subsidiary, broadening INVO's operational scale while allowing for the potential introduction of its INVOcell technology. The acquisition aligns with INVO's strategy to expand its network of fertility clinics while also enhancing patient access to advanced reproductive treatments.
Read more →-IVF
Jan 5, 2023INVO Bioscience Enters Distribution Agreement For Taiwan
INVO Bioscience, a fertility company, has announced a distribution agreement with Ming Mei Technology Co. Ltd for its INVOcell device in Taiwan. This exclusive agreement, effective for an initial year with renewals, positions INVO to leverage Ming Mei's significant market coverage and expertise in reproductive medicine. The INVOcell system aims to address challenges in fertility treatment, particularly in regions experiencing declining birth rates and increasing treatment costs. The partnership represents a strategic move to enhance access to advanced fertility solutions in Taiwan.
Read more →-IVF
Nov 14, 2022INVO Bioscience Reports Third Quarter 2022 Financial Results Company to Host Conference Call Today at 4:30pm
Bioscience Reports Third Quarter 2022 Financial Results to Host Conference Call Today at 4:30pm ET Fla., Nov. 14, 2022 /PRNewswire/ - INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced tr
Read more →-IVF
Aug 15, 2022DRAFT INVO Bioscience Reports Second Quarter 2022 Financial Results Company to Host Conference Call Today at 4:30pm
Bioscience Reports Second Quarter 2022 Financial Results to Host Conference Call Today at 4:30pm ET Florida, August 15, 2022 - INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment
Read more →-IVF
May 16, 2022INVO Bioscience Reports First Quarter 2022 Financial Results Company to Host Conference Call Today at 4:30pm
Bioscience Reports First Quarter 2022 Financial Results to Host Conference Call Today at 4:30pm ET Fla., May 16, 2022 /PRNewswire/ - INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced tre
Read more →-IVF
Mar 31, 2022INVO Bioscience Reports 2021 Financial Results Company to Host Conference Call Today at 4:30pm ET; Slide Presentation Also Available
Bioscience Reports 2021 Financial Results to Host Conference Call Today at 4:30pm ET; Slide Presentation Also Available Fla., March 31, 2022 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to a
Read more →-IVF
Nov 15, 2021INVO Bioscience Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update Company to Host Conference Call Today at 4:30pm ET (Details Below)
INVO Bioscience Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update to Host Conference Call Today at 4:30pm ET (Details Below) Fla., Nov. 15, 2021 /PRNewswire/ - INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a medical devic
Read more →-IVF
Nov 8, 2021INVO Bioscience Regains Full U.S. Commercialization Rights
Bioscience Regains Full U.S. Commercialization Rights Florida - November 8, 2021 - INVO Bioscience, Inc. ("INVO" or the "Company") (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), today announced it will regain
Read more →-IVF
Aug 16, 2021INVO Bioscience Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update Company to Host Conference Call Today at 4:30pm ET (Details Below)
INVO Bioscience Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update Company to Host Conference Call Today at 4:30pm ET (Details Below) SARASOTA, Fla., August 16, 2021 - INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focuse
Read more →-IVF
Jun 30, 2021INVO Bioscience Signs Joint Venture Agreement with Bloom Fertility to Open an INVOcell Fertility Clinic in Atlanta INVO Bioscience and established reproductive specialist Dr. Sue Ellen Carpenter, MD of Bloom Fertility to
Bioscience Signs Joint Venture Agreement with Bloom Fertility to Open an INVOcell Fertility Clinic in Atlanta Bioscience and established reproductive specialist Dr. Sue Ellen Carpenter, MD of Bloom Fertility today announce their partnership to make INVOcell, an innovative techn
Read more →-IVF
Jun 15, 2021INVO Bioscience Appoints Andrea Goren as Chief Financial Officer
Bioscience Appoints Andrea Goren as Chief Financial Officer Florida - June 15, 2021 - INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell , an effective and affordable tre
Read more →-IVF
May 17, 2021INVO Bioscience Reports First Quarter 2021 Financial and Operating Results and Provides Business Update Company to Host Conference Call Today at 4:30pm ET (Details Below)
Bioscience Reports First Quarter 2021 Financial and Operating Results and Provides Business Update to Host Conference Call Today at 4:30pm ET (Details Below) Fla., May 17, 2021 - INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative trea
Read more →-IVF
Oct 11, 2017INVO Bioscience Appoints Michael J. Campbell and Steven M. Shum to Its Board of Directors
INVO Bioscience Appoints Michael J. Campbell and Steven M. Shum to Its Board of Directors MEDFORD, Mass., October 11, 2017 -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell , today ann
Read more →-IVF
Apr 11, 2017INVO Bioscience Appoints Renowned Fertility Specialist Dr. Kevin Doody to Its Board of Directors
INVO Bioscience Appoints Renowned Fertility Specialist Dr. Kevin Doody to Its Board of Directors MEDFORD, Mass., April 11, 2017 -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, INVOcell , tod
Read more →-IVF
Nov 3, 2015INVO Bioscience Receives FDA Clearance for INVOcell Fertility Treatment Revolutionary device and procedure provides natural, safe, effective and economical fertility treatment option. Contact: Kathl
INVO Bioscience Receives FDA Clearance for INVOcell Fertility Treatment Revolutionary device and procedure provides natural, safe, effective and economical fertility treatment option. Contact: Kathleen Karloff, CEO INVO Bioscience, Inc. 978-878-9505 ext. 504 www.invobioscienc
Read more →-IVF
Nov 3, 2009RESERVE EQUITY FINANCING AGREEMENT THIS AGREEMENT dated as of the 28 day of October, 2009 (the "Agreement") between AGS Capital Group, LLC a New York limited liability corporation (the "Investor"), and INVO Bioscience, I
RESERVE EQUITY FINANCING THIS AGREEMENT dated as of the 28 day of October, 2009 (the "Agreement") between AGS Capital Group, LLC a New York limited liability corporation (the "Investor"), and INVO Bioscience, Inc., a corporation organized and existing under the laws of the S
Read more →-IVF
Sep 16, 2009INVO Bioscience Announces the Closing to the Bridge Financing
INVO Bioscience Announces the Closing to the Bridge Financing BEVERLY, Mass., September 16, 2009 -INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced that the $500,000 private placement /
Read more →-IVF
Dec 12, 2008Unassociated Document BIOXCELL, INC. (A DEVELOPMENT STAGE COMPANY) CONTENTS PAGE 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM PAGE 2 BALANCE SHEET AS OF DECEMBER 31, 2007 PAGE 3 STATEMENT OF OPERATIONS FOR T
DEVELOPMENT STAGE COMPANY) PAGE 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM PAGE 2 BALANCE SHEET AS OF DECEMBER 31, 2007 PAGE 3 STATEMENT OF OPERATIONS FOR THE PERIOD JANUARY 5, 2007 (INCEPTION) TO DECEMBER 31, 2007. PAGE 4 STATEMENT OF CHANGES IN STOCKHOLDERS' DEF
Read more →Competitive Position
How IVF ranks across every disease it competes inCompetitive Position is a premium feature
See how IVF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial